Physician profile
Grace L Shih
NPI 1528004447
$7,467.31
in general payments reported to CMS, 2019-2025
31 companies · $2,011 in 2025
The $2,011 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,019 · 2020: $277 · 2021: $186 · 2022: $972 · 2023: $1,177 · 2024: $1,825 · 2025: $2,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,960 · Education: $53.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,959.53 |
| Education | $53.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,943.45 | 2019-2025 | Linzess, Viberzi, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,536.43 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $682.83 | 2019-2025 | Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $452.56 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $424.20 | 2019-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $231.19 | 2023-2025 | Dupixent |
| Celgene Corporation | $208.54 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $201.27 | 2023-2025 | |
| Pfizer INC. | $193.42 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $189.94 | 2024-2025 | Iqirvo, Bylvay |
| Ardelyx, INC. | $185.37 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $143.32 | 2023-2025 | |
| Nestle Healthcare Nutrition INC. | $135.45 | 2022-2023 | |
| Intercept Pharmaceuticals, INC. | $127.75 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $114.51 | 2019-2023 | Dificid |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $104.47 | 2019-2023 | Sutab |
| Ironwood Pharmaceuticals, INC | $89.51 | 2019-2024 | Linzess |
| Aimmune Therapeutics, INC. | $61.47 | 2024-2025 | Zenpep |
| Qol Medical, LLC | $58.68 | 2022-2025 | Sucraid |
| Lilly USA, LLC | $50.45 | 2024-2025 | Omvoh |
| Alnylam Pharmaceuticals INC. | $50.16 | 2024-2025 | Givlaari |
| Madrigal Pharmaceuticals | $48.25 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $46.59 | 2019-2023 | Rebyota |
| Medtronic, INC. | $36.94 | 2025 | Synchromedii |
| Amgen INC. | $29.31 | 2020 | |
| Evoke Pharma, INC. | $28.88 | 2024-2025 | |
| Novo Nordisk INC | $22.69 | 2025 | Wegovy |
| Redhill Biopharma INC. | $21.54 | 2024 | Talicia |
| Alexion Pharmaceuticals, INC. | $16.63 | 2022 | |
| Sun Pharmaceutical Industries INC. | $16.40 | 2019 | |
| Boston Scientific Corporation | $15.11 | 2025 | General - Metal Stents - G.I. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Shih listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.